Matches in Wikidata for { <http://www.wikidata.org/entity/Q64652443> ?p ?o ?g. }
Showing items 1 to 60 of
60
with 100 items per page.
- Q64652443 description "clinical trial" @default.
- Q64652443 description "ensayu clínicu" @default.
- Q64652443 description "klinisch onderzoek" @default.
- Q64652443 description "клінічне випробування" @default.
- Q64652443 name "A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)" @default.
- Q64652443 type Item @default.
- Q64652443 label "A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)" @default.
- Q64652443 prefLabel "A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)" @default.
- Q64652443 P1050 Q64652443-F6DDCF3E-3380-41F5-9254-25A269577D01 @default.
- Q64652443 P1132 Q64652443-13D72D9D-C431-472E-B864-DCB17AF32E1E @default.
- Q64652443 P1476 Q64652443-3D023381-423B-4136-8A81-715D80AC94B1 @default.
- Q64652443 P17 Q64652443-153206DB-0BD5-4F5A-8305-E4B99437BDE9 @default.
- Q64652443 P17 Q64652443-57930EFA-7710-4A3F-A67D-3B68AC7A95ED @default.
- Q64652443 P17 Q64652443-5AC3DCE7-D2E7-4BCB-9816-2258EE252DEE @default.
- Q64652443 P17 Q64652443-8A5002E9-DD9B-4569-B460-113F9C3F92C8 @default.
- Q64652443 P17 Q64652443-9EA825A4-80D3-4645-90D5-0214DFCE1D2F @default.
- Q64652443 P17 Q64652443-A9AE790F-FDC1-44D5-9931-3591E8ADBA72 @default.
- Q64652443 P17 Q64652443-C3564159-CE88-4464-9F0C-C348193CEC85 @default.
- Q64652443 P17 Q64652443-F48E8B7F-F968-4E56-A178-5BFEB6A79EF8 @default.
- Q64652443 P17 Q64652443-F4947CD8-080C-4D44-A8DD-D714F9F79C0B @default.
- Q64652443 P17 Q64652443-F8042CE1-467B-4D98-80C8-0E5B4DD51579 @default.
- Q64652443 P17 Q64652443-FC35F1CC-526C-4405-B35B-97F8323D3C3D @default.
- Q64652443 P17 Q64652443-FF93F6D8-93C7-4B19-B4F1-F57041F28634 @default.
- Q64652443 P2899 Q64652443-5E32EF80-3499-43A9-BAEE-471A065BF036 @default.
- Q64652443 P3098 Q64652443-99E4B8C5-CE34-4B2B-A9C2-6129D387FF70 @default.
- Q64652443 P31 Q64652443-A128CEC5-10D3-4356-9E42-C8EEEAA83A7F @default.
- Q64652443 P580 Q64652443-9A2043DF-F40F-469A-8C98-C6B88F410666 @default.
- Q64652443 P582 Q64652443-02949824-FC56-4E52-BB7C-3A8B9C875916 @default.
- Q64652443 P6099 Q64652443-4E8461E8-BFA7-4CAA-8F9C-9A13403E9A37 @default.
- Q64652443 P6153 Q64652443-105FAA74-563B-4277-BD13-EA87FBC10829 @default.
- Q64652443 P6153 Q64652443-2B69CCAE-FD49-4707-9174-34E1E3CD62DF @default.
- Q64652443 P6153 Q64652443-320770F3-9D13-4698-A6CE-02FD7A100648 @default.
- Q64652443 P8363 Q64652443-735E13A1-2BE7-41BD-B580-D2CA002F574E @default.
- Q64652443 P859 Q64652443-8373FC37-7170-4200-89A6-E8FF9E86F0F9 @default.
- Q64652443 P1050 Q41112 @default.
- Q64652443 P1132 "+629" @default.
- Q64652443 P1476 "A Phase III, Multi-Center, Randomized, 24 Week, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-Blind Treatment Period" @default.
- Q64652443 P17 Q142 @default.
- Q64652443 P17 Q145 @default.
- Q64652443 P17 Q218 @default.
- Q64652443 P17 Q28 @default.
- Q64652443 P17 Q30 @default.
- Q64652443 P17 Q33 @default.
- Q64652443 P17 Q34 @default.
- Q64652443 P17 Q408 @default.
- Q64652443 P17 Q414 @default.
- Q64652443 P17 Q668 @default.
- Q64652443 P17 Q739 @default.
- Q64652443 P17 Q96 @default.
- Q64652443 P2899 "+18" @default.
- Q64652443 P3098 "NCT01192867" @default.
- Q64652443 P31 Q30612 @default.
- Q64652443 P580 "2010-12-11T00:00:00Z" @default.
- Q64652443 P582 "2014-05-26T00:00:00Z" @default.
- Q64652443 P6099 Q42824827 @default.
- Q64652443 P6153 Q16188802 @default.
- Q64652443 P6153 Q39997 @default.
- Q64652443 P6153 Q4403855 @default.
- Q64652443 P8363 Q78089383 @default.
- Q64652443 P859 Q212646 @default.